Last Close
Apr 10  •  04:00PM ET
28.21
Dollar change
-0.27
Percentage change
-0.95
%
Index
-
P/E
-
EPS (ttm)
-1.17
Insider Own
31.76%
Shs Outstand
709.69M
Perf Week
-0.42%
Market Cap
20.19B
Forward P/E
-
EPS next Y
-1.18
Insider Trans
-10.56%
Shs Float
488.39M
Perf Month
-4.63%
Enterprise Value
16.47B
PEG
-
EPS next Q
-0.29
Inst Own
68.32%
Perf Quarter
29.52%
Income
-809.24M
P/S
1516.90
EPS this Y
-366.11%
Inst Trans
2.15%
Perf Half Y
75.98%
Sales
13.31M
P/B
4.69
EPS next Y
-5.54%
ROA
-14.69%
Perf YTD
30.00%
Book/sh
6.02
P/C
4.45
EPS next 5Y
-
ROE
-17.11%
52W High
30.33 -6.99%
Perf Year
192.33%
Cash/sh
6.33
P/FCF
-
EPS past 3/5Y
42.73% -99.51%
ROIC
-18.53%
52W Low
9.24 205.30%
Perf 3Y
282.25%
Dividend Est.
-
EV/EBITDA
-
Sales past 3/5Y
-19.30% -
Gross Margin
60.46%
Volatility
2.47% 3.32%
Perf 5Y
186.98%
Dividend TTM
-
EV/Sales
1237.51
EPS Y/Y TTM
-751.06%
Oper. Margin
-9130.53%
ATR (14)
0.99
Perf 10Y
-
Dividend Ex-Date
-
Quick Ratio
30.66
Sales Y/Y TTM
-86.36%
Profit Margin
-6079.94%
RSI (14)
54.56
Dividend Gr. 3/5Y
- -
Current Ratio
30.66
EPS Q/Q
-262.80%
SMA20
1.71%
Beta
1.22
Payout
-
Debt/Eq
0.03
Sales Q/Q
-77.83%
SMA50
3.82%
Rel Volume
0.50
Prev Close
28.48
Employees
750
LT Debt/Eq
0.02
SMA200
46.00%
Avg Volume
6.22M
Price
28.21
IPO
Dec 08, 2020
Option/Short
Yes / Yes
Trades
Volume
3,119,664
Change
-0.95%
Date Action Analyst Rating Change Price Target Change
Mar-20-26Initiated Bernstein Outperform $35
Sep-02-25Initiated Citigroup Buy $16
Jul-10-25Resumed Goldman Buy $19
Feb-15-24Initiated Wolfe Research Outperform $17
Jan-05-24Initiated Piper Sandler Overweight $20
Dec-12-23Initiated Deutsche Bank Buy $14
Oct-17-23Initiated Guggenheim Buy $17
Jun-08-23Initiated BofA Securities Neutral $10.50
Oct-27-22Initiated JP Morgan Overweight $7
May-23-22Initiated SVB Leerink Outperform $6
Apr-02-26 05:00AM
05:00AM
Mar-28-26 03:00PM
Mar-04-26 04:04PM
02:35PM
09:55AM Loading…
09:55AM
09:15AM
09:01AM
08:40AM
08:14AM
Mar-03-26 04:15PM
07:00AM
Feb-14-26 01:29AM
Feb-10-26 06:41AM
Feb-08-26 08:39AM
06:38AM Loading…
Feb-07-26 06:38AM
Feb-06-26 02:05PM
02:00PM
01:25PM
10:10AM
10:03AM
08:15AM
07:00AM
07:00AM
Feb-01-26 07:47AM
Jan-23-26 04:15PM
Jan-20-26 10:31AM
Jan-02-26 10:50AM
Dec-22-25 08:10AM
Dec-11-25 07:30AM
02:00AM Loading…
Dec-10-25 02:00AM
02:00AM
Nov-10-25 02:01PM
08:25AM
07:00AM
Nov-06-25 09:15AM
Nov-05-25 09:10AM
Nov-04-25 07:30AM
Oct-27-25 04:10PM
Oct-21-25 05:52AM
Oct-04-25 04:54PM
Sep-29-25 08:01PM
Sep-23-25 12:00PM
Sep-22-25 10:21AM
Sep-18-25 10:47AM
10:34AM
Sep-17-25 04:11PM
12:49PM
07:00AM
Sep-14-25 04:00AM
Sep-11-25 04:30PM
11:11AM
Sep-03-25 01:01PM
Aug-28-25 11:49PM
Aug-12-25 06:42PM
03:02AM
Aug-11-25 04:58PM
08:15AM
07:00AM
Aug-08-25 09:17AM
Aug-07-25 06:15PM
Aug-05-25 08:10AM
Jul-28-25 04:05PM
Jul-24-25 11:47PM
Jul-11-25 06:20AM
Jun-24-25 12:45PM
Jun-16-25 07:00AM
Jun-09-25 04:05PM
May-29-25 08:15AM
07:00AM
May-28-25 02:17PM
09:15AM
May-15-25 05:15PM
04:10PM
May-14-25 05:40PM
May-13-25 05:10PM
May-08-25 07:45AM
May-06-25 06:20AM
May-02-25 10:37AM
Apr-29-25 11:35AM
Apr-23-25 12:13PM
Apr-21-25 04:08PM
10:18AM
07:00AM
07:00AM
Apr-14-25 06:20AM
Apr-11-25 03:07PM
10:04AM
Apr-10-25 05:08PM
Mar-31-25 04:03PM
Mar-29-25 04:00PM
Mar-25-25 02:12PM
Mar-19-25 04:04PM
09:26AM
07:45AM
Mar-18-25 04:32PM
Mar-03-25 09:15AM
Feb-25-25 08:00AM
Feb-12-25 10:00AM
Feb-10-25 07:00AM
Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. Its product portfolio includes Vtama, Batoclimab, Brepocitinib, Namilumab, and RVT-2001, which aims to treat psoriasis, atopic dermatitis, thyroid eye disease, and other illnesses. The company was founded by Vivek Ramaswamy on April 7, 2014 and is headquartered in London, the United Kingdom.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Humes JenniferChief Accounting OfficerApr 08 '26Sale28.3713,538384,07384,191Apr 10 06:00 PM
JENNIFER HUMESOfficerApr 08 '26Proposed Sale28.3713,538384,035Apr 08 04:07 PM
Fitzgerald MeghanDirectorMar 26 '26Option Exercise8.8070,000616,000112,963Mar 30 09:01 PM
Fitzgerald MeghanDirectorMar 26 '26Sale27.4570,0001,921,50042,963Mar 30 09:01 PM
MEGHAN FITZGERALDDirectorMar 26 '26Proposed Sale27.4570,0001,921,458Mar 26 04:14 PM
Venker EricPresident & Immunovant CEOMar 17 '26Option Exercise3.85200,000770,0001,847,546Mar 19 06:36 PM
Venker EricPresident & Immunovant CEOMar 17 '26Sale28.24200,0005,648,0001,647,546Mar 19 06:36 PM
Epperly Melissa B,DirectorMar 16 '26Sale28.6841,8611,200,57315,804Mar 18 06:23 PM
Venker EricOfficerMar 17 '26Proposed Sale28.24200,0005,648,836Mar 17 04:17 PM
MELISSA B EPPERLYDirectorMar 16 '26Proposed Sale28.6841,8611,200,498Mar 16 04:04 PM
Torti FrankPresident and Vant ChairFeb 19 '26Option Exercise3.851,400,0005,390,00015,136,547Feb 23 08:40 PM
Torti FrankPresident and Vant ChairFeb 20 '26Option Exercise3.851,012,6103,898,54814,749,157Feb 23 08:40 PM
Torti FrankPresident and Vant ChairFeb 23 '26Option Exercise3.85587,3902,261,45214,323,937Feb 23 08:40 PM
Torti FrankPresident and Vant ChairFeb 19 '26Sale27.421,400,00038,388,00013,736,547Feb 23 08:40 PM
Torti FrankPresident and Vant ChairFeb 20 '26Sale27.151,012,61027,492,36213,736,547Feb 23 08:40 PM
Torti FrankPresident and Vant ChairFeb 23 '26Sale27.51587,39016,159,09913,736,547Feb 23 08:40 PM
FRANK TORTIOfficerFeb 20 '26Proposed Sale27.521,600,00044,032,000Feb 20 04:29 PM
FRANK TORTIOfficerFeb 19 '26Proposed Sale27.481,400,00038,472,000Feb 19 04:24 PM
Venker EricPresident & Immunovant CEOFeb 13 '26Option Exercise3.85200,000770,0001,854,597Feb 18 05:57 PM
Venker EricPresident & Immunovant CEOFeb 13 '26Sale26.49200,0005,298,0001,654,597Feb 18 05:57 PM
MANCHESTER KEITH SDirectorFeb 12 '26Sale26.75425,00011,367,00015,503,113Feb 13 09:02 PM
MANCHESTER KEITH SDirectorFeb 11 '26Sale26.67425,00011,334,75015,928,113Feb 13 09:02 PM
MANCHESTER KEITH SDirectorFeb 13 '26Sale26.50375,7849,956,76815,127,329Feb 13 09:02 PM
Gold Daniel AllenDirectorFeb 12 '26Sale26.75425,00011,367,00015,503,113Feb 13 09:00 PM
Gold Daniel AllenDirectorFeb 11 '26Sale26.67425,00011,334,75015,928,113Feb 13 09:00 PM
Gold Daniel AllenDirectorFeb 13 '26Sale26.50375,7849,956,76815,127,329Feb 13 09:00 PM
QVT Financial LPDirector by DeputizationFeb 12 '26Sale26.75425,00011,367,00015,503,113Feb 13 08:45 PM
QVT Financial LPDirector by DeputizationFeb 11 '26Sale26.67425,00011,334,75015,928,113Feb 13 08:45 PM
QVT Financial LPDirector by DeputizationFeb 13 '26Sale26.50375,7849,956,76815,127,329Feb 13 08:45 PM
Venker EricOfficerFeb 13 '26Proposed Sale26.49200,0005,298,373Feb 13 04:21 PM
Sukhatme MayukhPresident & CIOFeb 09 '26Option Exercise12.68651,5588,261,75519,488,105Feb 11 05:53 PM
Sukhatme MayukhPresident & CIOFeb 09 '26Sale26.47339,4418,985,00319,148,664Feb 11 05:53 PM
Sukhatme MayukhOfficerFeb 09 '26Proposed Sale26.47339,4418,985,276Feb 09 04:13 PM
Venker EricPresident & Immunovant CEOJan 12 '26Option Exercise3.85200,000770,0001,854,597Jan 14 09:00 PM
Venker EricPresident & Immunovant CEOJan 12 '26Sale21.92200,0004,384,0001,654,597Jan 14 09:00 PM
Venker EricOfficerJan 12 '26Proposed Sale21.92200,0004,383,694Jan 12 04:04 PM
Sukhatme MayukhPresident & CIODec 31 '25Option Exercise12.682,449,87731,064,44021,286,424Dec 31 09:00 PM
Sukhatme MayukhPresident & CIODec 29 '25Option Exercise12.68748,3589,489,17919,584,905Dec 31 09:00 PM
Sukhatme MayukhPresident & CIODec 31 '25Sale21.711,018,99522,122,38120,267,429Dec 31 09:00 PM
Sukhatme MayukhPresident & CIODec 29 '25Sale21.74311,8736,780,11919,273,032Dec 31 09:00 PM
Sukhatme MayukhOfficerDec 31 '25Proposed Sale21.711,018,99522,119,828Dec 31 04:30 PM
Pulik RichardCFODec 23 '25Option Exercise3.85260,0001,001,000646,144Dec 29 09:00 PM
Pulik RichardCFODec 23 '25Sale22.43406,7319,122,307239,413Dec 29 09:00 PM
Venker EricPresident & Immunovant CEODec 23 '25Option Exercise3.85313,8411,208,2881,811,749Dec 29 09:00 PM
Venker EricPresident & Immunovant CEODec 24 '25Option Exercise3.85117,848453,7151,729,597Dec 29 09:00 PM
Venker EricPresident & Immunovant CEODec 23 '25Sale22.45200,0004,490,0001,611,749Dec 29 09:00 PM
Venker EricPresident & Immunovant CEODec 24 '25Sale22.5375,0001,689,7501,654,597Dec 29 09:00 PM
Sukhatme MayukhOfficerDec 29 '25Proposed Sale21.74311,8736,781,263Dec 29 04:31 PM
ERIC VENKEROfficerDec 24 '25Proposed Sale22.5375,0001,689,562Dec 29 09:36 AM
FRANK M TORTIOfficerDec 24 '25Proposed Sale22.4764,8911,458,373Dec 29 09:05 AM
RICHARD PULIKOfficerDec 23 '25Proposed Sale22.45260,0005,835,726Dec 23 04:19 PM
RICHARD PULIK TRUSTOfficerDec 23 '25Proposed Sale22.39146,7313,285,755Dec 23 04:07 PM
ERIC VENKEROfficerDec 23 '25Proposed Sale22.45200,0004,490,540Dec 23 04:04 PM
Sukhatme MayukhPresident & CIODec 17 '25Option Exercise12.6859,513754,62518,896,060Dec 19 09:04 PM
Sukhatme MayukhPresident & CIODec 17 '25Sale23.0926,831619,52818,869,229Dec 19 09:04 PM
Gold Daniel AllenDirectorDec 16 '25Sale23.04917,28221,129,61917,130,445Dec 18 07:54 PM
Gold Daniel AllenDirectorDec 17 '25Sale23.07777,33217,935,59516,353,113Dec 18 07:54 PM
MANCHESTER KEITH SDirectorDec 16 '25Sale23.04917,28221,129,61917,130,445Dec 18 07:52 PM
MANCHESTER KEITH SDirectorDec 17 '25Sale23.07777,33217,935,59516,353,113Dec 18 07:52 PM
QVT Financial LPDirector by DeputizationDec 16 '25Sale23.04917,28221,129,61917,130,445Dec 18 07:41 PM
QVT Financial LPDirector by DeputizationDec 17 '25Sale23.07777,33217,935,59516,353,113Dec 18 07:41 PM
Gline MatthewCEODec 15 '25Option Exercise12.163,870,65947,062,04919,559,933Dec 17 09:00 PM
Gline MatthewCEODec 15 '25Sale21.681,740,00037,723,20017,290,820Dec 17 09:00 PM
Sukhatme MayukhOfficerDec 17 '25Proposed Sale23.0926,831619,488Dec 17 05:09 PM
Ramaswamy Vivek10% OwnerDec 12 '25Option Exercise12.684,672,72459,250,14038,326,479Dec 15 09:34 PM
Ramaswamy Vivek10% OwnerDec 11 '25Option Exercise12.681,869,69123,707,68235,523,447Dec 15 09:34 PM
Ramaswamy Vivek10% OwnerDec 15 '25Option Exercise12.68832,45310,555,50434,486,208Dec 15 09:34 PM
Ramaswamy Vivek10% OwnerDec 12 '25Sale21.961,975,85843,389,84236,350,621Dec 15 09:34 PM
Ramaswamy Vivek10% OwnerDec 11 '25Sale21.64774,14216,752,43334,749,305Dec 15 09:34 PM
Ramaswamy Vivek10% OwnerDec 15 '25Sale22.05353,7457,800,07734,132,463Dec 15 09:34 PM
Gline MatthewOfficerDec 15 '25Proposed Sale21.681,740,00037,723,200Dec 15 04:36 PM
Roivant Sciences Ltd.DirectorDec 12 '25Buy21.0016,666,666349,999,986113,317,007Dec 12 05:17 PM
Venker EricPresident & Immunovant CEODec 09 '25Option Exercise3.85200,000770,0001,697,908Dec 11 09:00 PM
Venker EricPresident & Immunovant CEODec 09 '25Sale20.85200,0004,170,0001,497,908Dec 11 09:00 PM
Venker EricOfficerDec 09 '25Proposed Sale20.85200,0004,169,131Dec 09 04:49 PM
MANCHESTER KEITH SDirectorNov 19 '25Sale20.231,300,00026,304,50018,047,727Nov 21 08:24 PM
Gold Daniel AllenDirectorNov 19 '25Sale20.231,300,00026,304,50018,047,727Nov 21 08:22 PM
QVT Financial LPDirector by DeputizationNov 19 '25Sale20.231,300,00026,304,50018,047,727Nov 21 08:15 PM
Ramaswamy Vivek10% OwnerNov 14 '25Sale20.331,027,67020,892,53134,193,406Nov 17 05:52 PM
Ramaswamy Vivek10% OwnerNov 17 '25Sale20.51539,65011,068,22233,653,756Nov 17 05:52 PM
Ramaswamy Vivek10% OwnerNov 13 '25Sale20.81287,2835,978,35935,221,076Nov 17 05:52 PM
Venker EricPresident & Immunovant CEONov 07 '25Option Exercise3.85200,000770,0001,704,959Nov 07 09:00 PM
Venker EricPresident & Immunovant CEONov 07 '25Sale20.22200,0004,044,0001,504,959Nov 07 09:00 PM
Venker EricOfficerNov 07 '25Proposed Sale20.22200,0004,043,960Nov 07 03:15 PM
Venker EricPresident & Immunovant CEOOct 15 '25Option Exercise15.85414,6836,572,7261,919,642Oct 17 09:00 PM
Venker EricPresident & Immunovant CEOOct 16 '25Option Exercise15.85318,2825,044,7701,823,241Oct 17 09:00 PM
Venker EricPresident & Immunovant CEOOct 17 '25Option Exercise15.85118,4181,876,9251,623,377Oct 17 09:00 PM
Venker EricPresident & Immunovant CEOOct 15 '25Sale16.93414,6837,020,5831,504,959Oct 17 09:00 PM
Venker EricPresident & Immunovant CEOOct 16 '25Sale17.05318,2825,426,7081,504,959Oct 17 09:00 PM
Venker EricPresident & Immunovant CEOOct 17 '25Sale17.06118,4182,020,2111,504,959Oct 17 09:00 PM
Venker EricOfficerOct 17 '25Proposed Sale17.06118,4182,020,171Oct 17 04:01 PM
Venker EricOfficerOct 16 '25Proposed Sale17.05318,2825,425,645Oct 16 04:37 PM
Venker EricOfficerOct 15 '25Proposed Sale16.93414,6837,021,429Oct 15 04:23 PM
Venker EricPresident & Immunovant CEOOct 09 '25Option Exercise15.85104,9401,663,2991,609,899Oct 14 09:00 PM
Venker EricPresident & Immunovant CEOOct 13 '25Option Exercise15.8520,727328,5231,525,686Oct 14 09:00 PM
Venker EricPresident & Immunovant CEOOct 09 '25Sale16.30104,9401,710,5221,504,959Oct 14 09:00 PM
Venker EricPresident & Immunovant CEOOct 13 '25Sale16.2520,727336,8141,504,959Oct 14 09:00 PM
Venker EricOfficerOct 13 '25Proposed Sale16.2520,727336,877Oct 14 08:51 AM
Venker EricOfficerOct 09 '25Proposed Sale16.30104,9401,710,040Oct 09 04:12 PM
Venker EricPresident & Immunovant CEOOct 07 '25Option Exercise7.21355,1612,559,0931,860,120Oct 08 09:00 PM
MP MP Materials Corporation daily Stock Chart
Index
-
P/E
-
EPS (ttm)
-0.52
Insider Own
19.31%
Shs Outstand
177.36M
Perf Week
11.08%
Market Cap
9.81B
Forward P/E
50.57
EPS next Y
1.09
Insider Trans
-3.00%
Shs Float
143.36M
Perf Month
-11.26%
Enterprise Value
9.43B
PEG
-
EPS next Q
-0.01
Inst Own
67.10%
Perf Quarter
-9.53%
Income
-85.87M
P/S
35.63
EPS this Y
226.13%
Inst Trans
0.63%
Perf Half Y
-21.75%
Sales
275.46M
P/B
4.95
EPS next Y
260.83%
ROA
-2.66%
Perf YTD
9.34%
Book/sh
11.16
P/C
5.36
EPS next 5Y
-
ROE
-4.98%
52W High
100.25 -44.90%
Perf Year
134.66%
Cash/sh
10.31
P/FCF
-
EPS past 3/5Y
- -13.01%
ROIC
-2.56%
52W Low
18.64 196.35%
Perf 3Y
106.89%
Dividend Est.
-
EV/EBITDA
-
Sales past 3/5Y
-19.47% 15.45%
Gross Margin
-2.80%
Volatility
4.45% 6.14%
Perf 5Y
51.80%
Dividend TTM
-
EV/Sales
34.24
EPS Y/Y TTM
-26.93%
Oper. Margin
-44.48%
ATR (14)
3.52
Perf 10Y
-
Dividend Ex-Date
-
Quick Ratio
6.67
Sales Y/Y TTM
35.12%
Profit Margin
-31.18%
RSI (14)
52.28
Dividend Gr. 3/5Y
- -
Current Ratio
7.24
EPS Q/Q
134.58%
SMA20
4.51%
Beta
1.79
Payout
-
Debt/Eq
0.43
Sales Q/Q
70.04%
SMA50
-3.06%
Rel Volume
0.61
Prev Close
53.90
Employees
998
LT Debt/Eq
0.40
SMA200
-9.68%
Avg Volume
7.11M
Price
55.24
IPO
Jun 22, 2020
Option/Short
Yes / Yes
Trades
Volume
4,362,405
Change
2.49%
Date Action Analyst Rating Change Price Target Change
Jan-13-26Initiated William Blair Outperform
Dec-05-25Upgrade Morgan Stanley Equal-Weight → Overweight $71
Nov-24-25Upgrade BMO Capital Markets Market Perform → Outperform $75
Nov-19-25Initiated Goldman Buy $77
Nov-14-25Upgrade JP Morgan Neutral → Overweight
Nov-10-25Upgrade Deutsche Bank Hold → Buy $71
Oct-09-25Resumed BMO Capital Markets Market Perform $76
Sep-23-25Initiated Daiwa Securities Outperform $80
Aug-01-25Upgrade Jefferies Hold → Buy $80
Jul-31-25Resumed Morgan Stanley Equal-Weight $65
Today 11:19AM
Apr-09-26 04:05PM
08:00AM
Apr-08-26 10:09AM
Apr-01-26 08:00AM
04:05PM Loading…
Mar-26-26 04:05PM
03:54PM
Mar-25-26 10:41AM
10:33AM
Mar-24-26 08:00AM
Mar-23-26 02:14PM
10:38AM
Mar-20-26 05:00AM
Mar-18-26 05:00AM
Mar-17-26 10:33AM
10:59AM Loading…
Mar-16-26 10:59AM
Mar-15-26 08:49PM
Mar-14-26 11:55AM
Mar-13-26 03:41PM
Mar-12-26 05:00AM
Mar-10-26 02:53PM
02:15PM
09:57AM
Mar-09-26 12:24PM
09:15AM
08:15AM
Mar-06-26 02:42PM
Mar-05-26 04:05PM
Mar-04-26 04:06PM
11:24AM
10:09AM Loading…
10:09AM
Mar-03-26 08:00AM
Mar-02-26 03:49PM
12:44PM
07:13AM
Feb-28-26 12:35PM
Feb-27-26 06:04PM
04:23PM
11:16AM
11:02AM
10:38AM
10:38AM
10:38AM
05:42AM
12:01AM
Feb-26-26 06:15PM
06:11PM
06:00PM
05:27PM
04:58PM
04:05PM
01:00PM
10:58AM
10:19AM
09:25AM
09:25AM
08:00AM
06:00AM
Feb-24-26 02:11PM
10:44AM
09:06AM
Feb-23-26 12:16PM
10:33AM
Feb-20-26 10:30AM
Feb-19-26 01:00PM
11:06AM
10:00AM
09:36AM
Feb-18-26 01:51PM
08:15AM
Feb-17-26 03:05PM
Feb-16-26 06:00AM
Feb-13-26 01:00PM
08:36AM
Feb-12-26 12:50PM
06:42AM
Feb-09-26 03:57PM
Feb-05-26 12:18PM
08:40AM
Feb-04-26 04:41PM
04:23PM
11:33AM
07:00AM
Feb-03-26 12:04PM
06:27AM
Feb-02-26 05:02PM
04:24PM
04:14PM
01:51PM
01:24PM
12:39PM
12:17PM
12:03PM
11:19AM
10:14AM
09:51AM
09:34AM
09:18AM
08:39AM
Jan-31-26 04:25PM
MP Materials Corp. engages in the production and marketing of rare earth specialty materials. It operates through the following segments: Materials and Magnetics. The Materials segment focuses on the operation of Mountain Pass, which produces refined rare earth oxides and related products, as well as rare earth concentrate products. The Magnetics segment is involved in the operation of Independence Facility, where the company began production of magnetic precursor products. The company was founded by James Henry Litinsky and Michael Rosenthal in 2017 and is headquartered in Las Vegas, NV.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hoops Elliot DeanGeneral Counsel and SecretaryMar 16 '26Sale60.0113,914834,97961,053Mar 17 08:20 PM
Corbett RyanChief Financial OfficerMar 17 '26Sale60.0046,0002,760,000129,017Mar 17 08:18 PM
Corbett RyanOfficerMar 17 '26Proposed Sale60.0046,0002,760,055Mar 17 04:31 PM
Elliot HoopsOfficerMar 16 '26Proposed Sale60.0113,914835,032Mar 16 04:11 PM
Hoops Elliot DeanGeneral Counsel and SecretaryJan 20 '26Sale68.217,823533,60774,967Jan 22 07:48 PM
Elliot HoopsofficerJan 20 '26Proposed Sale68.217,823533,569Jan 20 04:36 PM
Litinsky James H.Chairman and CEOJan 08 '26Sale64.17272,60017,492,74212,805,965Jan 09 09:48 PM
Litinsky James H.Chairman and CEOJan 07 '26Sale64.0127,4001,753,87413,078,565Jan 09 09:48 PM
JAMES HENRY LITINSKY REVOCABLEDirectorJan 08 '26Proposed Sale62.50272,60017,037,500Jan 08 04:25 PM
JAMES HENRY LITINSKY REVOCABLEDirectorJan 07 '26Proposed Sale59.8227,4001,639,068Jan 07 04:57 PM
Corbett RyanChief Financial OfficerDec 09 '25Sale60.0038,1462,288,760156,666Dec 10 09:11 PM
Corbett RyanOfficerDec 09 '25Proposed Sale60.0038,1462,288,760Dec 09 04:14 PM
Litinsky James H.Chairman and CEODec 05 '25Sale62.94385,00024,232,30813,105,965Dec 05 09:45 PM
JAMES HENRY LITINSKY REVOCABLEOfficerDec 05 '25Proposed Sale62.94385,00024,231,092Dec 05 04:29 PM
Litinsky James H.Chairman and CEONov 20 '25Sale63.86248,41115,864,58313,369,665Nov 20 09:40 PM
JAMES HENRY LITINSKY REVOCABLEOfficerNov 20 '25Proposed Sale63.86248,41115,864,147Nov 20 04:23 PM
Corbett RyanChief Financial OfficerNov 17 '25Sale57.7220,0001,154,400194,812Nov 19 09:21 PM
Corbett RyanOfficerNov 17 '25Proposed Sale57.7220,0001,154,480Nov 17 01:13 PM
Rosenthal Michael StuartChief Operating OfficerAug 29 '25Sale72.02150,00010,802,8381,284,409Aug 29 09:23 PM
Rosenthal Michael StuartOfficerAug 29 '25Proposed Sale72.02150,00010,803,255Aug 29 04:20 PM
Hoops Elliot DeanGeneral Counsel and SecretaryAug 01 '25Sale60.336,337382,3040Aug 01 09:22 PM
Hoops Elliot DeanOfficerAug 01 '25Proposed Sale60.296,337382,038Aug 01 03:58 PM
Hoops Elliot DeanGeneral Counsel and SecretaryJul 01 '25Sale31.946,338202,4646,337Jul 03 09:27 PM
Hoops Elliot DeanOfficerJul 01 '25Proposed Sale31.906,338202,209Jul 01 04:36 PM
Hoops Elliot DeanGeneral Counsel and SecretaryJun 26 '25Sale36.375,523200,87269,749Jun 27 09:30 PM
Hoops Elliot DeanOfficerJun 26 '25Proposed Sale36.335,523200,651Jun 26 04:17 PM
Hoops Elliot DeanGeneral Counsel and SecretaryJun 13 '25Sale29.965,538165,91812,675Jun 13 09:25 PM
Hoops Elliot DeanGeneral Counsel and SecretaryJun 12 '25Sale29.9580023,96018,213Jun 13 09:25 PM
Hoops Elliot DeanOfficerJun 13 '25Proposed Sale29.966,338189,900Jun 13 04:30 PM
Litinsky James H.Chairman and CEOApr 14 '25Sale27.08199,1805,393,79413,643,076Apr 16 09:11 PM